New data for Roche’s Evrysdi (risdiplam) demonstrate long-term efficacy and safety in a broad population of people with spinal muscular atrophy (SMA) March 16, 2022March 16, 2022 by / Share This.....LinkedinTwitterFacebookGoogleEmailRelated News: New three-year data for Roche’s Evrysdi (risdiplam)…Roche’s Evrysdi (risdiplam) granted FDA priority…Roche’s Evrysdi (risdiplam) granted FDA priority…Positive new data for Roche’s Evrysdi in largest…FDA approves Roche’s Evrysdi for use in babies under…Interim data from phase III HAVEN 6 study…
